TD Cowen raises target for Exagen stock from USD 10 to USD 11

Published on 10/18/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exagen posted USD 19.94 million revenue in the second quarter. Exagen stock is due to report Q3 on November 3, 2026 after an adjusted loss of USD 0.13.

Analyst view and reporting date

TD Cowen raised its Exagen target from USD 10.00 to USD 11.00 on October 13, 2026.
Second-quarter revenue reached USD 19.94 million, while adjusted loss was USD 0.13 per share.
Exagen is scheduled to report third-quarter results on November 3, 2026.

XGN, US30068X1037, Illustration mit AI erstellt.

Exagen stock (ISIN US30068X1037) is heading toward its next results date after TD Cowen raised its price target from USD 10.00 to USD 11.00 on October 13, 2026. According to Markets Insider, analyst Dan Brennan retained a Buy rating while citing volume growth and margin opportunities.

Target rises ahead of results

The target change places TD Cowen above Exagen's second-quarter operating evidence but below the most bullish recent view. MarketBeat reported on October 16, 2026 that nine analysts held a Moderate Buy consensus, with an average 12-month target of USD 9.75 and individual targets from USD 8.00 to USD 12.00.

The latest reported quarter ended June 30, 2026. Exagen generated USD 19.94 million in revenue and a net loss of USD 3.20 million, while diluted earnings per share were negative USD 0.13. Revenue exceeded the USD 17.80 million consensus cited by MarketBeat, giving the analyst case a quantified operating reference.

What does the target mean for margins?

TD Cowen's October 13 note tied its constructive view to Exagen's addressable market, volume growth and margin opportunities, rather than to reported profitability. The company says its AVISE testing portfolio supports diagnosis, prognosis and monitoring of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, and targets about 5,000 rheumatologists in the United States, according to Exagen.

Three dated milestones

On August 4, 2026, Exagen reported second-quarter revenue of USD 19.94 million. On September 11, 2026, B. Riley Financial initiated coverage with a Buy rating and a USD 12.00 target, as reported by MarketBeat. On October 13, 2026, TD Cowen lifted its target from USD 10.00 to USD 11.00.

Next reporting date

MarketBeat lists November 3, 2026, as the expected announcement date for Exagen's third-quarter results, with the conference call scheduled for 8:30 a.m. ET. Its consensus calls for third-quarter revenue of USD 18.34 million and earnings per share of negative USD 0.19.

Results will test the thesis

The November report will show whether the revenue trajectory and margin opportunity cited in the target raise are translating into a narrower loss. Exagen's 52-week range was USD 2.59 to USD 12.23 as of October 16, 2026. The further course of trading is shown by the continuously updated real-time quote of Exagen stock.